Evidence map›Paper›PMID 40226992›Full record

ReviewCNS spectrums2025

Urgency to treat and early optimized treatment in major depressive disorder: consequences of delayed treatment, barriers to implementation, and practical strategies for clinicians.

Oloruntoba J Oluboka, Jeffrey Habert, Atul Khullar, David J Robinson, Martin A Katzman, Larry J Klassen, Claudio N Soares, Pratap R Chokka, Margaret A Oakander, Roger S McIntyre and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS spectrums, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Oloruntoba J OlubokaDepartment of Psychiatry, University of Calgary, Calgary, AB, Canada.ORCID 0000-0003-2161-6720
Jeffrey HabertDepartment of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
Atul KhullarDepartment of Psychiatry, University of Calgary, Edmonton, AB, Canada.
David J RobinsonPsychiatry Clinic, Canadian Mental Health Association, London, ON, Canada.
Martin A KatzmanSTART Clinic for Mood and Anxiety Disorders, Toronto, ON, Canada.
Larry J KlassenEden Mental Health Center, Winkler, MB, Canada.
Claudio N SoaresDepartment of Psychiatry, Queen's University School of Medicine, Kingston, ON, Canada.
Pratap R ChokkaChokka Center for Integrative Health, Edmonton, AB, Canada.ORCID 0000-0002-1043-8554
Margaret A OakanderDepartment of Psychiatry, University of Calgary, Calgary, AB, Canada.
Roger S McIntyreDepartment of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-4733-2523
Diane McIntoshDepartment of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Pierre BlierRoyal Ottawa Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.
Sidney H KennedyHomewood Research Institute, Guelph, ON, Canada.
Matthieu BoucherMedical Affairs, Otsuka Canada Pharmaceuticals Inc., Saint-Laurent, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major depressive disorder (MDD) is a serious and often chronic illness that requires early and urgent treatment. Failing to provide effective treatment of MDD can worsen the illness trajectory, negatively impact physical health, and even alter brain structure. Early optimized treatment (EOT) of MDD, with a measurement-based approach to diagnosis, rapid treatment initiation with medication dosage optimization, frequent monitoring, and prompt adjustments in treatment planning when indicated, should proceed with a sense of urgency. In this article, we describe common barriers to providing an EOT approach to treating MDD at each phase of care, along with strategies for navigating these obstacles. Approaching the treatment of MDD with a greater sense of urgency increases the likelihood of symptom reduction in MDD, facilitating full functional recovery and a return to life engagement.

Indexed as

Antidepressive AgentsMajor Depressive DisorderHumansTreatment DelayAntidepressive AgentsAdjunctive therapymajor depressive disorderpharmacotherapytime-to-treatmenttreatment optimizationurgency to treat

Identifiers

PMID40226992
PMCPMC13064778

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.